Latest News

IBM Not Immune to Macro Headwinds- UBS

IBM Not Immune to Macro Headwinds- UBS

UBS cut IBM's price target to $112 from $118 on Wednesday, maintaining a Sell rating on the stock, stating the company is not immune to macro.Analyst David Vogt also lowered estimates as...

  • Investing.com

Related Articles